These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31088556)

  • 1. Anti-collagen type v: a marker of early systemic sclerosis?
    Ugolini-Lopes MR; Mantovani E; Bonoldi VLN; de Medeiros Ribeiro AC; Bonfá E; Yoshinari N; Andrade D
    Adv Rheumatol; 2019 May; 59(1):19. PubMed ID: 31088556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
    Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Autoimmunity to Peptides of Collagen V α1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis.
    Velosa APP; Brito L; de Jesus Queiroz ZA; Carrasco S; Tomaz de Miranda J; Farhat C; Goldenstein-Schainberg C; Parra ER; de Andrade DCO; Silva PL; Capelozzi VL; Teodoro WR
    Front Immunol; 2020; 11():604602. PubMed ID: 33643291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury.
    Assous N; Allanore Y; Batteux F; Meune C; Toulon P; Weill B; Kahan A
    Clin Exp Rheumatol; 2005; 23(2):199-204. PubMed ID: 15895890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study.
    Juhl P; Bay-Jensen AC; Karsdal M; Siebuhr AS; Franchimont N; Chavez J
    PLoS One; 2018; 13(12):e0207324. PubMed ID: 30507931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study.
    Juhl P; Vinderslev Iversen L; Karlsmark T; Asser Karsdal M; Bay-Jensen AC; Mogensen M; Siebuhr AS
    Biomarkers; 2019 Jun; 24(4):373-378. PubMed ID: 30821519
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study.
    Rozman B; Cucnik S; Sodin-Semrl S; Czirják L; Varjú C; Distler O; Huscher D; Aringer M; Steiner G; Matucci-Cerinic M; Guiducci S; Stamenkovic B; Stankovic A; Kveder T
    Ann Rheum Dis; 2008 Sep; 67(9):1282-6. PubMed ID: 18063672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.
    Dumoitier N; Chaigne B; Régent A; Lofek S; Mhibik M; Dorfmüller P; Terrier B; London J; Bérezné A; Tamas N; Varin-Blank N; Mouthon L
    Arthritis Rheumatol; 2017 May; 69(5):1078-1089. PubMed ID: 27992693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma.
    Danielides S; Mavragani CP; Katsakoulas I; Zintzaras E; Drosos AA; Vlachoyiannopoulos PG; Moutsopoulos HM
    Scand J Rheumatol; 2011; 40(4):299-303. PubMed ID: 21417550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody profile in the experimental model of scleroderma induced by type V human collagen.
    Callado MR; Viana VS; Vendramini MB; Leon EP; Bueno C; Velosa AP; Teodoro WR; Yoshinari NH
    Immunology; 2007 Sep; 122(1):38-46. PubMed ID: 17442023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Risk Score impact on susceptibility to systemic sclerosis.
    Bossini-Castillo L; Villanueva-Martin G; Kerick M; Acosta-Herrera M; López-Isac E; Simeón CP; Ortego-Centeno N; Assassi S; ; ; ; ; Hunzelmann N; Gabrielli A; de Vries-Bouwstra JK; Allanore Y; Fonseca C; Denton CP; Radstake TR; Alarcón-Riquelme ME; Beretta L; Mayes MD; Martin J
    Ann Rheum Dis; 2021 Jan; 80(1):118-127. PubMed ID: 33004331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cyclic citrullinated peptide antibodies in scleroderma patients.
    Polimeni M; Feniman D; Skare TS; Nisihara RM
    Clin Rheumatol; 2012 May; 31(5):877-80. PubMed ID: 22215120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database.
    Schneeberger D; Tyndall A; Kay J; Søndergaard KH; Carreira PE; Morgiel E; Deuschle K; Derk CT; Widuchowska M; Walker UA
    Rheumatology (Oxford); 2013 Mar; 52(3):560-7. PubMed ID: 23221323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex.
    Mecoli CA; Adler BL; Yang Q; Hummers LK; Rosen A; Casciola-Rosen L; Shah AA
    Arthritis Rheumatol; 2021 Feb; 73(2):315-323. PubMed ID: 33241644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological pulmonary vascular remodeling is induced by type V collagen in a model of scleroderma.
    Marangoni RG; Korman BD; Parra ER; Velosa APP; Barbeiro HV; Martins V; Dos Santos ABG; Soriano F; Teodoro WR; Silva PL; Tourtellotte W; Capelozzi VL; Varga J; Yoshinari NH
    Pathol Res Pract; 2021 Apr; 220():153382. PubMed ID: 33647866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.